Daily Stock Analysis, EDAP, Edap Tms SA, priceseries

Edap Tms SA. Daily Stock Analysis
Stock Information
Open
4.53
Close
4.61
High
4.76
Low
4.45
Previous Close
4.60
Daily Price Gain
0.01
YTD High
5.42
YTD High Date
Apr 11, 2019
YTD Low
1.78
YTD Low Date
Jan 2, 2019
YTD Price Change
2.74
YTD Gain
146.52%
52 Week High
5.42
52 Week High Date
Apr 11, 2019
52 Week Low
1.35
52 Week Low Date
Dec 21, 2018
52 Week Price Change
2.23
52 Week Gain
93.70%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 5. 2017
2.77
Jun 20. 2017
3.41
11 Trading Days
23.11%
Link
LONG
Dec 31. 2018
1.85
Jan 28. 2019
2.64
18 Trading Days
42.53%
Link
LONG
Apr 2. 2019
4.25
Apr 17. 2019
4.75
11 Trading Days
11.87%
Link
LONG
Aug 28. 2019
3.47
Aug 29. 2019
3.70
1 Trading Days
6.69%
Link
LONG
Sep 3. 2019
3.28
Sep 25. 2019
4.18
16 Trading Days
27.31%
Link
Company Information
Stock Symbol
EDAP
Exchange
NasdaqGM
Company URL
http://www.edap-tms.com
Company Phone
69120 VAULX EN VELIN I0
CEO
Marc Oczachowski
Headquarters
-
Business Address
PARC D'ACTIVITES LA POUDRETTE LAMARTINE, 4 RUE DU DAUPHINE
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Appliances & Equipment
CIK
0001041934
About

EDAP TMS SA develops, produces and markets minimally invasive medical devices for urological diseases. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. In March 2013, the company introduced a new innovative HIFU device, the Focal One dedicated to focal therapy of prostate cancer. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Description

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS). The HIFU division develops, manufactures, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology. It offers Ablatherm, a HIFU device for the treatment of organ-confined prostate cancer, referred to as T1-T2 stage; and Focal One device, a HIFU robotic device for the focal therapy of localized prostate cancer. This division also leases equipment; sells disposables and spare parts; and offers maintenance services. The UDS division develops, manufactures, markets, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders, primarily urinary stones and other clinical indications. It offers lithotripters, such as Sonolith i-move and Sonolith i-sys for the treatment of urinary tract stones by means of extracorporeal shockwave lithotripsy technology. This division also leases lithotripters; sells disposables and spare parts; and provides maintenance services. The company markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is based in Vaulx-en-Velin, France.